You've heard the warning: testosterone therapy causes prostate cancer. It's a sticky idea, and it's worth understanding what the number behind it — PSA — actually does on therapy, and how a provider reads it.
Start with what PSA is (and isn't)
Prostate-specific antigen is a protein made by the prostate gland. It shows up in blood in small amounts, and the level tends to drift upward with age as the prostate enlarges. It is not a cancer test in the yes/no sense; it's a signal that a provider interprets in context — your age, your baseline, prostate size, and how the number moves over time [1].
Testosterone influences the prostate. That's real biology, not marketing fear. But the old assumption — more testosterone equals runaway prostate growth and cancer — has not held up the way it was once feared. The current framework is the "saturation model": prostate tissue's androgen receptors appear to be near-saturated at relatively low testosterone concentrations, so once you're above that point, adding more testosterone produces little additional prostate stimulation [2]. That's the mechanism worth understanding before you fixate on the headline.
ng/mL · marker = Historic reference point
Source: [4] Prostate-Specific Antigen (PSA) Test — NCI, National Cancer Institute
What the evidence actually shows
Large reviews and society guidance have consistently failed to demonstrate that testosterone therapy causes prostate cancer in men who are appropriately screened and monitored. The Endocrine Society's clinical practice guideline treats testosterone therapy as appropriate for men with diagnosed hypogonadism, paired with structured prostate monitoring — not as a contraindication driven by cancer fear [1].
More recently, the TRAVERSE trial — a large randomized, placebo-controlled cardiovascular safety study in middle-aged and older men with hypogonadism — reported low rates of prostate events and did not show a signal of increased high-grade prostate cancer over the study period with structured monitoring [3]. That is not a promise of safety for any individual, and it does not mean testosterone is right for you. It means the modern picture is monitoring and shared decision-making, not blanket avoidance.
The honest caveat: no study eliminates risk, and a provider will not start therapy if your baseline screening raises concern. That's the point of the number.
What monitoring actually looks like
For a fifty-something man considering testosterone, prostate monitoring is a defined process, not a vibe. Society guidance frames it roughly like this [1]:
- Baseline first. A PSA and a clinical assessment before starting. If baseline findings are concerning, evaluation comes before any therapy decision.
- A recheck window early on. PSA is reassessed after starting therapy, when a testosterone-related change would typically show itself.
- Ongoing periodic monitoring. Continued PSA checks on a schedule the provider sets, with attention to the *trend* rather than any single reading.
The reason for the early recheck is straightforward: starting testosterone in a man whose levels were low can produce a modest PSA rise as the prostate responds to being in a more normal androgen environment. That small early bump is often expected, not alarming.
Source: [1] Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
Signal versus noise: what a provider is actually watching
Here's the part that reframes the fear. A provider isn't spooked by PSA moving; they're watching *how* it moves.
Noise includes: a small early rise after starting therapy; day-to-day and lab-to-lab variability; transient elevations from things unrelated to cancer — recent ejaculation, vigorous cycling, a urinary infection, or prostate inflammation. PSA is famously twitchy, which is exactly why one number in isolation is a weak basis for any decision [1][4].
Signal is a pattern: a confirmed rise beyond expected variation, a rapid rate of change over time (velocity), or a level that crosses a threshold the provider considers meaningful for your age — especially if a physical exam finding accompanies it. Guidelines describe using a confirmed increase over a defined amount within the first year, or an abnormal exam, as a trigger for urology referral and further evaluation rather than an automatic diagnosis [1].
The practical takeaway: a single elevated PSA doesn't mean cancer and doesn't mean stopping therapy. It means confirm, contextualize, and — if the pattern warrants — refer. That is the system working, not failing.
For the optimizer: PSA lives inside a bigger panel
If you're already thinking about the full hormone picture — testosterone, estradiol, the downstream markers — PSA is one input among several a thorough provider tracks. Testosterone therapy can affect red blood cell mass (hematocrit), and estradiol matters because a share of testosterone converts to estrogen via aromatase; both are part of responsible monitoring, not afterthoughts [1]. A provider who treats you as a high-performer engages with the whole panel and adjusts based on repeat labs — which is the opposite of a set-and-forget refill.
A note for the man weighing testosterone as "the strongest option": testosterone therapy is for men with a genuine, provider-diagnosed indication — not a default performance lever. And if weight is the real target, the hormone conversation and the metabolic conversation are separate. Some men explore compounded formulations for various therapies. Where compounding comes up: Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
What to bring to a first conversation
- Your most recent PSA, if you have one — it becomes your baseline reference.
- Any prostate or urinary symptoms, family history, and prior screening results.
- Your actual goal, stated plainly. "I want my numbers moving this year" and "I want my recovery and edge back" lead to different conversations, and both deserve a real workup rather than a guess.
The fear that testosterone quietly causes prostate cancer is best answered not by reassurance but by a monitoring plan you can see: baseline, early recheck, trend tracking, and a defined threshold for referral. When the number rises a little, that's often the body responding as expected. When it rises in a pattern, that's what the process is built to catch.
*This article is educational and is not medical advice. It is not a diagnosis or a recommendation to start any specific medication. Whether testosterone therapy is appropriate — and whether any prescription is issued — is decided by an independent licensed provider based on your evaluation.*
Where Velri fits
Velri is a technology and coordination company — not a medical practice. Velri can help coordinate lab work, connect you with an independent, licensed provider for evaluation and any monitoring they deem appropriate, and — only if that provider prescribes — coordinate fulfillment through an independent, licensed pharmacy. A prescription is never guaranteed and is always the independent provider's clinical decision.
